363 related articles for article (PubMed ID: 17478055)
21. Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntington's disease.
Ciamei A; Morton AJ
Neurobiol Learn Mem; 2009 Oct; 92(3):417-28. PubMed ID: 19524696
[TBL] [Abstract][Full Text] [Related]
22. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice.
Ortiz AN; Kurth BJ; Osterhaus GL; Johnson MA
Neurosci Lett; 2011 Mar; 492(1):11-4. PubMed ID: 21256185
[TBL] [Abstract][Full Text] [Related]
23. Direct Visualisation of Abnormal Dendritic Spine Morphology in the Hippocampus of the R6/2 Transgenic Mouse Model of Huntington's Disease.
Bulley SJ; Drew CJ; Morton AJ
J Huntingtons Dis; 2012; 1(2):267-73. PubMed ID: 25063335
[TBL] [Abstract][Full Text] [Related]
24. Chronic constant light-induced hippocampal late-phase long-term potentiation impairment in vitro is attenuated by antagonist of D1/D5 receptors.
Chai AP; Ma WP; Wang LP; Cao J; Xu L; Yang YX; Mao RR
Brain Res; 2015 Oct; 1622():72-80. PubMed ID: 26115584
[TBL] [Abstract][Full Text] [Related]
25. Deficits in development of synaptic plasticity in rat dorsal striatum following prenatal and neonatal exposure to low-dose bisphenol A.
Zhou R; Zhang Z; Zhu Y; Chen L; Sokabe M; Chen L
Neuroscience; 2009 Mar; 159(1):161-71. PubMed ID: 19162132
[TBL] [Abstract][Full Text] [Related]
26. Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.
Dallérac GM; Cummings DM; Hirst MC; Milnerwood AJ; Murphy KP
Neuromolecular Med; 2016 Mar; 18(1):146-53. PubMed ID: 26782175
[TBL] [Abstract][Full Text] [Related]
27. Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice.
Johnson MA; Villanueva M; Haynes CL; Seipel AT; Buhler LA; Wightman RM
J Neurochem; 2007 Dec; 103(5):2102-10. PubMed ID: 17868298
[TBL] [Abstract][Full Text] [Related]
28. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
29. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
30. Dopamine D1/5 receptor-mediated long-term potentiation of intrinsic excitability in rat prefrontal cortical neurons: Ca2+-dependent intracellular signaling.
Chen L; Bohanick JD; Nishihara M; Seamans JK; Yang CR
J Neurophysiol; 2007 Mar; 97(3):2448-64. PubMed ID: 17229830
[TBL] [Abstract][Full Text] [Related]
31. Endogenous dopamine amplifies ischemic long-term potentiation via D1 receptors.
Saulle E; Centonze D; Martín AB; Moratalla R; Bernardi G; Calabresi P
Stroke; 2002 Dec; 33(12):2978-84. PubMed ID: 12468800
[TBL] [Abstract][Full Text] [Related]
32. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
33. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
34. Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression.
Mancini M; Ghiglieri V; Bagetta V; Pendolino V; Vannelli A; Cacace F; Mineo D; Calabresi P; Picconi B
Neuropharmacology; 2016 Feb; 101():341-50. PubMed ID: 26471421
[TBL] [Abstract][Full Text] [Related]
35. Cdk5 Modulates Long-Term Synaptic Plasticity and Motor Learning in Dorsolateral Striatum.
Hernandez A; Tan C; Mettlach G; Pozo K; Plattner F; Bibb JA
Sci Rep; 2016 Jul; 6():29812. PubMed ID: 27443506
[TBL] [Abstract][Full Text] [Related]
36. Altered cortical glutamate receptor function in the R6/2 model of Huntington's disease.
André VM; Cepeda C; Venegas A; Gomez Y; Levine MS
J Neurophysiol; 2006 Apr; 95(4):2108-19. PubMed ID: 16381805
[TBL] [Abstract][Full Text] [Related]
37. Heterosynaptic co-activation of glutamatergic and dopaminergic afferents is required to induce persistent long-term potentiation.
O'Carroll CM; Morris RG
Neuropharmacology; 2004 Sep; 47(3):324-32. PubMed ID: 15275821
[TBL] [Abstract][Full Text] [Related]
38. Activation of spinal d1/d5 receptors induces late-phase LTP of C-fiber-evoked field potentials in rat spinal dorsal horn.
Yang HW; Zhou LJ; Hu NW; Xin WJ; Liu XG
J Neurophysiol; 2005 Aug; 94(2):961-7. PubMed ID: 15829590
[TBL] [Abstract][Full Text] [Related]
39. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
40. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
